- Home
- DMLP vs ZYME Comparison
DMLP vs ZYME Comparison
Compare DMLP & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- ZYME
- Stock Information
- Founded
- DMLP 2003
- ZYME 2003
- Country
- DMLP United States
- ZYME United States
- Employees
- DMLP N/A
- ZYME N/A
- Industry
- DMLP Oil & Gas Production
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- ZYME Health Care
- Exchange
- DMLP Nasdaq
- ZYME Nasdaq
- Market Cap
- DMLP 1.1B
- ZYME 1.2B
- IPO Year
- DMLP N/A
- ZYME 2017
- Fundamental
- Price
- DMLP $22.88
- ZYME $19.62
- Analyst Decision
- DMLP
- ZYME Strong Buy
- Analyst Count
- DMLP 0
- ZYME 7
- Target Price
- DMLP N/A
- ZYME $22.00
- AVG Volume (30 Days)
- DMLP 145.5K
- ZYME 990.6K
- Earning Date
- DMLP 11-06-2025
- ZYME 11-06-2025
- Dividend Yield
- DMLP 14.06%
- ZYME N/A
- EPS Growth
- DMLP N/A
- ZYME N/A
- EPS
- DMLP 1.13
- ZYME N/A
- Revenue
- DMLP $143,803,000.00
- ZYME $134,481,000.00
- Revenue This Year
- DMLP N/A
- ZYME $99.52
- Revenue Next Year
- DMLP N/A
- ZYME N/A
- P/E Ratio
- DMLP $20.16
- ZYME N/A
- Revenue Growth
- DMLP N/A
- ZYME 116.21
- 52 Week Low
- DMLP $22.56
- ZYME $9.03
- 52 Week High
- DMLP $34.88
- ZYME $19.98
- Technical
- Relative Strength Index (RSI)
- DMLP 34.80
- ZYME 62.34
- Support Level
- DMLP $22.55
- ZYME $16.00
- Resistance Level
- DMLP $23.87
- ZYME $19.98
- Average True Range (ATR)
- DMLP 0.60
- ZYME 0.90
- MACD
- DMLP -0.18
- ZYME -0.09
- Stochastic Oscillator
- DMLP 13.19
- ZYME 92.83
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.